Scholarlink

<p>Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月24日

查看全文
  • Philippe Moreau,
  • Cyrille Hulin,
  • Alexis Talbot,
  • Hélène Demarquette,
  • Léo Caillot,
  • Thomas Chalopin,
  • Arthur Bobin,
  • Salomon Manier,
  • Xavier Leleu,
  • Lionel Karlin,
  • Denis Caillot,
  • Cécile Sonntag,
  • Pierre Feugier,
  • Murielle Roussel,
  • Romain Gounot,
  • Margaret Macro,
  • Mohamad Mohty,
  • Laurent Garderet,
  • Mourab Tiab,
  • Frédérique Orsini-Piocelle,
  • Laure Vincent,
  • Nathalie Meuleman,
  • Jean Fontan,
  • Lidia Montes,
  • Marie-Christiane Vekemans,
  • Martine Escoffre-Barbe,
  • Jean-Richard Eveillard,
  • Jean-Marc Schiano de Colella,
  • Jérôme Lambert,
  • Jean-Yves Mary,
  • Jean-Paul Fermand,
  • Bertrand Arnulf,
  • Jill Corre,
  • Hervé Avet-Loiseau,
  • Thierry Facon,
  • Jean-Luc Harousseau,
  • Cyrille Touzeau,
  • Aurore Perrot

摘要

Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.